P
Preethi Krishnan
Researcher at AbbVie
Publications - 50
Citations - 2478
Preethi Krishnan is an academic researcher from AbbVie. The author has contributed to research in topics: Glecaprevir & Pibrentasvir. The author has an hindex of 25, co-authored 47 publications receiving 2211 citations.
Papers
More filters
Journal ArticleDOI
Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial
Xavier Forns,Samuel S. Lee,Joaquin Mario Valdes,Sabela Lens,Reem Ghalib,Humberto Aguilar,Franco Felizarta,Tarek Hassanein,Holger Hinrichsen,Diego Rincón,Rosa Maria Morillas,Stefan Zeuzem,Yves Horsmans,David R. Nelson,Yao Yu,Preethi Krishnan,Chih-Wei Lin,Jens Kort,Federico J. Mensa +18 more
TL;DR: The results show that 99% of patients treated with once-daily glecaprevir plus pibrentasvir achieved a sustained virological response at 12 weeks, and this drug regimen had a favourable safety profile in previously treated or untreated patients with chronic HCV genotype 1, 2, 4, 5, or 6 infection and compensated cirrhosis.
Journal ArticleDOI
Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis
Tarik Asselah,Kris V. Kowdley,Neddie Zadeikis,Stanley Wang,Tarek Hassanein,Yves Horsmans,Massimo Colombo,Filipe Calinas,Humberto Aguilar,Victor de Lédinghen,Parvez S. Mantry,Christophe Hézode,Rui Tato Marinho,Kosh Agarwal,Frederik Nevens,Magdy Elkhashab,Jens Kort,Ran Liu,Teresa I. Ng,Preethi Krishnan,C.-W. Lin,Federico J. Mensa +21 more
TL;DR: 8 weeks’ treatment with glecaprevir/pibrentasivr produced an SVR12 in at least 93% of patients with chronic HCV genotype 2, 4, 5, or 6 infection without cirrhosis, with virologic failure in less than 1%.
Journal ArticleDOI
Identification of host genes involved in hepatitis C virus replication by small interfering RNA technology
Teresa I. Ng,Hongmei Mo,Tami Pilot-Matias,Yupeng He,Gennadiy Koev,Preethi Krishnan,Rubina Mondal,Ron Pithawalla,Wenping He,Tanya Dekhtyar,Jeremy C.L. Packer,Mark Schurdak,Akhteruzzaman Molla +12 more
TL;DR: Findings of this study may provide important information for understanding HCV replication and may constitute a novel set of targets for HCV antiviral therapy.
Journal ArticleDOI
Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection
Nancy Reau,Paul Y. Kwo,Susan Rhee,Robert S. Brown,Kosh Agarwal,Peter W Angus,Edward Gane,Jia-Horng Kao,Parvez S. Mantry,David Mutimer,K. Rajender Reddy,Tram T. Tran,Yiran B Hu,Abhishek Gulati,Preethi Krishnan,Emily O. Dumas,Ariel Porcalla,Nancy S. Shulman,Wei Liu,Suvajit Samanta,Roger Trinh,Xavier Forns +21 more
TL;DR: Once‐daily glecaprevir/pibrentasvir for 12 weeks is a well‐tolerated and efficacious, ribavirin‐free treatment for patients with chronic HCV GT1‐6 infection who have received a liver or kidney transplant.
Journal ArticleDOI
In Vitro and In Vivo Antiviral Activity and Resistance Profile of Ombitasvir, an Inhibitor of Hepatitis C Virus NS5A
Preethi Krishnan,Jill Beyer,Neeta Mistry,G. Koev,Thomas Reisch,David A. Degoey,Warren M. Kati,Campbell Andrew L,Laura A. Williams,Wangang Xie,Carolyn M. Setze,Akhteruzzaman Molla,Christine Collins,Tami Pilot-Matias +13 more
TL;DR: Ombitasvir (ABT-267) is a hepatitis C virus (HCV) NS5A inhibitor with picomolar potency, pan-genotypic activity, and 50% effective concentrations (EC 50 s) of 0.82 to 19.3 pM against HCV genotypes 1 to 5 and 366pM against genotype 6a as discussed by the authors.